Logo image of PSAT.PA

PASSAT (PSAT.PA) Stock Fundamental Analysis

Europe - EPA:PSAT - FR0000038465 - Common Stock

4.36 EUR
+0.01 (+0.23%)
Last: 9/30/2025, 7:00:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to PSAT. PSAT was compared to 13 industry peers in the Broadline Retail industry. The financial health of PSAT is average, but there are quite some concerns on its profitability. PSAT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

PSAT had positive earnings in the past year.
In the past year PSAT has reported a negative cash flow from operations.
PSAT had positive earnings in each of the past 5 years.
In multiple years PSAT reported negative operating cash flow during the last 5 years.
PSAT.PA Yearly Net Income VS EBIT VS OCF VS FCFPSAT.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M 6M 8M

1.2 Ratios

PSAT's Return On Assets of 1.68% is on the low side compared to the rest of the industry. PSAT is outperformed by 76.92% of its industry peers.
PSAT has a Return On Equity of 2.77%. This is in the lower half of the industry: PSAT underperforms 69.23% of its industry peers.
PSAT's Return On Invested Capital of 3.76% is on the low side compared to the rest of the industry. PSAT is outperformed by 61.54% of its industry peers.
PSAT had an Average Return On Invested Capital over the past 3 years of 6.18%. This is below the industry average of 10.04%.
Industry RankSector Rank
ROA 1.68%
ROE 2.77%
ROIC 3.76%
ROA(3y)3.75%
ROA(5y)3.66%
ROE(3y)5.84%
ROE(5y)5.33%
ROIC(3y)6.18%
ROIC(5y)6.63%
PSAT.PA Yearly ROA, ROE, ROICPSAT.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2 4 6 8

1.3 Margins

PSAT has a worse Profit Margin (1.84%) than 76.92% of its industry peers.
In the last couple of years the Profit Margin of PSAT has declined.
With a Operating Margin value of 4.43%, PSAT is not doing good in the industry: 69.23% of the companies in the same industry are doing better.
PSAT's Operating Margin has declined in the last couple of years.
PSAT has a better Gross Margin (57.77%) than 84.62% of its industry peers.
PSAT's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 4.43%
PM (TTM) 1.84%
GM 57.77%
OM growth 3Y-10.04%
OM growth 5Y-4.36%
PM growth 3Y-1.4%
PM growth 5Y-17.24%
GM growth 3Y1.53%
GM growth 5Y0.6%
PSAT.PA Yearly Profit, Operating, Gross MarginsPSAT.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

5

2. Health

2.1 Basic Checks

PSAT has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, PSAT has less shares outstanding
The number of shares outstanding for PSAT has been reduced compared to 5 years ago.
PSAT has a worse debt/assets ratio than last year.
PSAT.PA Yearly Shares OutstandingPSAT.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
PSAT.PA Yearly Total Debt VS Total AssetsPSAT.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

PSAT has an Altman-Z score of 2.97. This is not the best score and indicates that PSAT is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.97, PSAT is doing worse than 69.23% of the companies in the same industry.
PSAT has a Debt/Equity ratio of 0.20. This is a healthy value indicating a solid balance between debt and equity.
PSAT has a better Debt to Equity ratio (0.20) than 84.62% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Altman-Z 2.97
ROIC/WACC0.48
WACC7.86%
PSAT.PA Yearly LT Debt VS Equity VS FCFPSAT.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M 40M

2.3 Liquidity

A Current Ratio of 3.33 indicates that PSAT has no problem at all paying its short term obligations.
The Current ratio of PSAT (3.33) is better than 76.92% of its industry peers.
A Quick Ratio of 2.28 indicates that PSAT has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.28, PSAT is in the better half of the industry, outperforming 76.92% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.33
Quick Ratio 2.28
PSAT.PA Yearly Current Assets VS Current LiabilitesPSAT.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

1

3. Growth

3.1 Past

The earnings per share for PSAT have decreased strongly by -47.28% in the last year.
PSAT shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -7.94% yearly.
PSAT shows a decrease in Revenue. In the last year, the revenue decreased by -2.55%.
The Revenue has been growing by 11.13% on average over the past years. This is quite good.
EPS 1Y (TTM)-47.28%
EPS 3Y14.36%
EPS 5Y-7.94%
EPS Q2Q%-10.54%
Revenue 1Y (TTM)-2.55%
Revenue growth 3Y15.78%
Revenue growth 5Y11.13%
Sales Q2Q%-1.92%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PSAT.PA Yearly Revenue VS EstimatesPSAT.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2

4. Valuation

4.1 Price/Earnings Ratio

PSAT is valuated correctly with a Price/Earnings ratio of 15.03.
Compared to the rest of the industry, the Price/Earnings ratio of PSAT indicates a rather cheap valuation: PSAT is cheaper than 84.62% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.70, PSAT is valued a bit cheaper.
Industry RankSector Rank
PE 15.03
Fwd PE N/A
PSAT.PA Price Earnings VS Forward Price EarningsPSAT.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

PSAT's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PSAT is cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.13
PSAT.PA Per share dataPSAT.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for PSAT!.
Industry RankSector Rank
Dividend Yield N/A

PASSAT

EPA:PSAT (9/30/2025, 7:00:00 PM)

4.36

+0.01 (+0.23%)

Chartmill FA Rating
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustryBroadline Retail
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners5.79%
Ins Owner ChangeN/A
Market Cap18.31M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 15.03
Fwd PE N/A
P/S 0.29
P/FCF N/A
P/OCF N/A
P/B 0.44
P/tB 0.5
EV/EBITDA 1.13
EPS(TTM)0.29
EY6.65%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS14.84
BVpS9.83
TBVpS8.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.68%
ROE 2.77%
ROCE 5.45%
ROIC 3.76%
ROICexc 6.45%
ROICexgc 7.56%
OM 4.43%
PM (TTM) 1.84%
GM 57.77%
FCFM N/A
ROA(3y)3.75%
ROA(5y)3.66%
ROE(3y)5.84%
ROE(5y)5.33%
ROIC(3y)6.18%
ROIC(5y)6.63%
ROICexc(3y)11.28%
ROICexc(5y)12.99%
ROICexgc(3y)12.56%
ROICexgc(5y)14.63%
ROCE(3y)8.95%
ROCE(5y)9.61%
ROICexcg growth 3Y-6.11%
ROICexcg growth 5Y-9.64%
ROICexc growth 3Y-8.19%
ROICexc growth 5Y-9.07%
OM growth 3Y-10.04%
OM growth 5Y-4.36%
PM growth 3Y-1.4%
PM growth 5Y-17.24%
GM growth 3Y1.53%
GM growth 5Y0.6%
F-Score3
Asset Turnover0.92
Health
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Debt/EBITDA 1.6
Cap/Depr 93.3%
Cap/Sales 3.77%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.33
Quick Ratio 2.28
Altman-Z 2.97
F-Score3
WACC7.86%
ROIC/WACC0.48
Cap/Depr(3y)83.8%
Cap/Depr(5y)95.29%
Cap/Sales(3y)2.98%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-47.28%
EPS 3Y14.36%
EPS 5Y-7.94%
EPS Q2Q%-10.54%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-2.55%
Revenue growth 3Y15.78%
Revenue growth 5Y11.13%
Sales Q2Q%-1.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-11.45%
EBIT growth 3Y4.16%
EBIT growth 5Y6.28%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-137.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-104.15%
OCF growth 3YN/A
OCF growth 5YN/A